首页> 外文期刊>Comparative clinical pathology >Monitoring of heparin therapy and establishment of an optimal therapy scheme for thrombosis prophylaxis in a pig model for human catheter interventions
【24h】

Monitoring of heparin therapy and establishment of an optimal therapy scheme for thrombosis prophylaxis in a pig model for human catheter interventions

机译:监测肝素治疗并建立预防人导管干预的猪模型血栓形成的最佳治疗方案

获取原文
获取原文并翻译 | 示例
           

摘要

This study aims to investigate variables suitable for monitoring of unfractionated heparin (UFH) therapy and establishment of an optimal therapy scheme in pigs. This is a prospective study of 32 pigs undergoing catheterization for endovascular embolization of experimentally induced arteriovenous malformation. Pigs were assigned to four groups receiving different UFH treatment during catheter intervention. In groups 1 and 2, UFH was applied as a bolus of either 100 IU/kg (n = 6) and 200 IU/kg (n = 6). Groups 3 and 4 received a continuous infusion of 66 IU/kg/h UFH (n = 10) and 100 IU/kg/h (n = 10), respectively, which was applied 20 min after an initial bolus of 100 IU/kg. Blood samples were taken 0, 10, 20, 40, 60, 100, and 140 min after starting catheterization (groups 1 + 2) and after 0, 10, 20, 30, 40, 50, 60, 80, 100, 120, and 140 min, respectively (groups 3 + 4). High/low range activated coagulation time (LR-ACT), activated partial thromboplastin time (aPTT), prothrombin time, fibrinogen, and anti-FactorXa activity (FXa) activity were assessed. Based on anti-FXa activity, bolus injection of 100 and 200 IU/kg UFH had a mean half-life of 28. 43 ± 8. 85 and 57. 05 ± 12. 42 min, however, an aPTT exceeding 999 s was present in four of seven pigs in group 2. In group 3, aPTT increased from baseline 15 ± 2 s to a steady state ranging from 30 to 33 s. In group 4, there was an increase of aPTT to 58 ± 23 s 140 min after initiation of treatment. Suitable variables for monitoring UFH therapy included anti-FXa activity, aPTT, and LR-ACT. An initial bolus of 100 IU/kg followed by a continuous UFH infusion of 66 IU UFH/kg/h can be recommended as antithrombotic therapy during catheterization.
机译:这项研究旨在研究适用于监测普通肝素(UFH)治疗的变量,并建立适合猪的最佳治疗方案。这是对32头进行导管插入术的猪进行前瞻性研究的实验结果,这些插入物用于实验诱发的动静脉畸形的血管内栓塞。将猪分为四组,在导管干预期间接受不同的UFH处理。在第1组和第2组中,UFH分别以100 IU / kg(n = 6)和200 IU / kg(n = 6)推注。第3组和第4组分别连续输注66 IU / kg / h UFH(n = 10)和100 IU / kg / h(n = 10),在初始推注100 IU / kg后20分钟应用。在开始导管插入后(第1 + 2组),第0、10、20、30、40、50、60、80、100、120、0、10、20、40、60、100和140分钟采血和140分钟(第3 + 4组)。评估高/低范围活化凝血时间(LR-ACT),活化部分凝血活酶时间(aPTT),凝血酶原时间,纤维蛋白原和抗FactorXa活性(FXa)活性。根据抗FXa活性,推注100和200 IU / kg UFH的平均半衰期为28. 43±8。85和57. 05±12。42分钟,但是aPTT超过999 s在第2组的7只猪中有4只在第3组中,aPTT从基线的15±2 s增加到30到33 s的稳态。在第4组中,治疗开始后140分钟,aPTT增加至58±23 s。监测UFH治疗的合适变量包括抗FXa活性,aPTT和LR-ACT。建议在导管插入期间先推注100 IU / kg,然后连续UFH输注66 IU UFH / kg / h。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号